Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Dec 12, 2019	YANCOPOULOS GEORGE Director, President and CSO Trans History: 673	Director, President and CSO	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	77,767	$377.16	444,109
Nov 25, 2019	STAHL NEIL EVP Research and Development Trans History: 660	EVP Research and Development	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	5,994	$362.75	26,461
Nov 22, 2019	VAGELOS P ROY Director, Chairman of the Board Trans History: 742	Director, Chairman of the Board	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	23,989	$358.33	362,727
May 24, 2019	VAGELOS P ROY Director, Chairman of the Board Trans History: 742	Director, Chairman of the Board	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	80,164	$313.64	388,505
May 13, 2019	STAHL NEIL EVP Research and Development Trans History: 660	EVP Research and Development	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	15,147	$304.20	32,303
Dec 19, 2018	Fenimore Christopher R. VP Controller Trans History: 306	VP Controller	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	1,602	$364.42	8,269
Dec 13, 2018	SCHLEIFER LEONARD S Director, President & CEO Trans History: 427	Director, President & CEO	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	96,079	$377.31	363,014
Dec 13, 2018	SCHLEIFER LEONARD S Director, President & CEO Trans History: 427	Director, President & CEO	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	64,052	$377.31	423,962
Dec 13, 2018	YANCOPOULOS GEORGE Director, President and Chief Scientific Trans History: 673	Director, President and Chief Scientific	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	76,863	$377.31	73,137
Dec 13, 2018	YANCOPOULOS GEORGE Director, President and Chief Scientific Trans History: 673	Director, President and Chief Scientific	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	48,192	$377.31	118,993

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media